The evaluation of receptor data (oestrogen, progesterone and human epidermal growth factor receptor 2) was hampered by the poor reporting to the register, since these variables were not included from the start of the register: neither was the breast cancer gene (BRCA)-status part of the register. The gene discussed is ERBB2; the disease is breast carcinoma.